![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Publisher: Adis International
ISSN: 1173-5503
Source: PharmacoEconomics and Outcomes News, Vol.1, Iss.570, 2009-01, pp. : 9-9
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Botox injects meaningful improvements into QOL
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 640, 2011-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Measuring QOL in patients with acne
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 284, 2000-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Measuring QOL in rheumatoid arthritis
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 263, 2000-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Thyroxine plus liothyronine: no QOL benefit
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 439, 2003-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
No long-term QOL benefit for CRT
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 637, 2011-01 ,pp. :